Can Mounjaro help lower blood pressure — and what does the evidence actually show?

Imagine your last GP appointment: blood pressure slightly elevated, weight flagged, a conversation left half-finished

A lot of people reading this have been in that room. Numbers on a cuff that are nudging into the amber zone, a weight that has crept up over years, and a sense that the two things are linked but that nobody has quite spelled out what to do about either. It is a frustrating place to be. So let's be direct about what Mounjaro can and cannot offer here.

Excess body weight raises blood pressure through several routes: greater blood volume, increased resistance in vessel walls, hormonal shifts in the renin-angiotensin system, and elevated sympathetic nervous activity. Losing weight reliably reduces each of these. As a general rule, around 1 mmHg of systolic pressure is recovered for every kilogram lost, though individual responses vary considerably. Whether Mounjaro lowers blood pressure in practice therefore depends substantially on how much weight a person loses, and that figure can be large.

In SURMOUNT-1 (2,539 adults with obesity, no diabetes, 72 weeks), participants on the 15 mg dose lost an average of roughly 20–21% of body weight. Systolic blood pressure fell by an average of around 7 mmHg in that group. That is clinically meaningful, comparable, in size, to the effect of some antihypertensive medicines. The trial data were published in the New England Journal of Medicine and formed part of the evidence base reviewed by NICE.

The mechanism goes a little deeper than weight loss alone

Tirzepatide activates two receptors (GIP and GLP-1) that GLP-1-only medicines like semaglutide do not both engage. GLP-1 receptors are found in the heart, kidneys and blood vessels as well as the gut, and GLP-1 agonism has been associated with natriuresis (salt excretion via the kidneys), reduced arterial stiffness, and direct vasodilatory effects. Whether the GIP receptor adds meaningfully to these cardiovascular effects is still being studied, but the dual mechanism is one reason researchers are interested in tirzepatide's broader effects on blood pressure beyond what weight loss alone would predict.

It is honest to say this science is not fully settled. The blood pressure reductions seen in trials are real and consistent, but disentangling the weight-loss effect from any direct vascular mechanism is methodologically difficult. What is clear from the NHS's guidance on tirzepatide is that cardiovascular risk factors (including blood pressure, cholesterol and blood glucose) tend to improve alongside weight reduction on this medicine. The NHS medicines page for tirzepatide lists blood pressure changes among the effects that should be monitored during treatment.

If you are currently taking medication to manage blood pressure, there is a practical implication: as your blood pressure falls, your existing prescription may need to be reviewed. This is not a side effect to worry about (it is the kind of positive clinical problem your GP would be glad to encounter) but it does mean that starting Mounjaro is not simply a question of weight. Your prescriber needs the full picture, including what you are already taking, and our guide to how Mounjaro can help with blood pressure is a good place to build that understanding before your consultation. Our page on Mounjaro alongside blood pressure medications covers the interaction detail.

What the clinical licence says, and why it matters for how you approach this

Mounjaro holds a UK licence for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition such as hypertension, high cholesterol, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes. Hypertension explicitly sits on that list, so if your blood pressure is elevated and your BMI meets the threshold, that combination can be clinically relevant to your eligibility for treatment.

NICE recommended tirzepatide in December 2024 (Technology Appraisal TA1026) for NHS use in adults with a BMI of 35 or above plus at least one weight-related comorbidity. Private treatment through a regulated service has a broader eligible population, aligned to the licensed criteria above. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

None of this means Mounjaro is prescribed specifically to bring blood pressure down. It means the two things can move together, and that a prescriber will look at your whole health profile (weight, blood pressure, medications, history) before deciding whether this treatment is appropriate. That is exactly the kind of assessment our prescribers carry out. If you want to explore whether tirzepatide might suit your situation, you can find a full overview of how we work on our weight-loss treatments page.

A note on cost context: private Mounjaro treatment is priced per monthly pen and varies by dose and provider. Our Mounjaro pricing page sets out what is included in a single transparent price (consultation, prescription, delivery and aftercare) without subscriptions or hidden extras.